Comment on: Different treatment options for Takayasu arteritis patients with moderate-to- severe aortic regurgitation: long-term outcomes
Rheumatology (Oxford)
.
2021 Aug 2;60(8):e290-e291.
doi: 10.1093/rheumatology/keab184.
Authors
Keiichiro Kadoba
1
,
Ryu Watanabe
2
,
Motomu Hashimoto
2
,
Akio Morinobu
1
,
Chikashi Terao
1
3
4
5
,
Hajime Yoshifuji
1
Affiliations
1
Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan.
2
Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
3
Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
4
Clinical Research Center, Shizuoka General Hospital, University of Shizuoka, Shizuoka, Japan.
5
Department of Applied Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
PMID:
33617627
DOI:
10.1093/rheumatology/keab184
No abstract available
Publication types
Comment
MeSH terms
Aortic Valve Insufficiency* / etiology
Humans
Takayasu Arteritis* / complications
Takayasu Arteritis* / drug therapy